Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Itraconazole · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Itraconazole | DRUG | - |
| Amphotericin B | DRUG | - |
Inclusion Criteria Patients must have: * HIV positive or negative status. * Blastomycosis or histoplasmosis. * Life expectancy of at least 1 week. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Liver disease. * Self-limiting fungal ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Itraconazole is an antifungal small molecule studied in Phase 3 for treating fungal infections in people with HIV. The completed trial evaluated it in patients with blastomycosis or histoplasmosis, two invasive fungal diseases that occur in immunocompromised individuals. It was given both intravenously and as oral capsules.
Itraconazole is developed by Johnson & Johnson, which trades under the ticker JNJ. The company sponsored the Phase 3 study of the drug in patients with HIV infections who also had blastomycosis or histoplasmosis.
Itraconazole is in Phase 3 development for HIV Infections, specifically for fungal infections such as blastomycosis and histoplasmosis in patients with HIV. The single Phase 3 trial has been completed, and no trials are currently active.
Itraconazole was studied in one Phase 3 trial, NCT00002159, titled a randomized, open, comparative multicenter study of initial treatment with intravenous itraconazole versus amphotericin B followed by consolidation treatment with itraconazole capsules. The trial enrolled 60 patients in the United States and is completed.
The Phase 3 trial of itraconazole, NCT00002159, enrolled 60 patients. Participants were 13 years of age and older, of all sexes, and were not healthy volunteers. The study was conducted in the United States and is now completed.